Johnson & Johnson $JNJ Position Decreased by RWC Asset Management LLP

RWC Asset Management LLP lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 275,592 shares of the company’s stock after selling 20,593 shares during the period. Johnson & Johnson accounts for 2.5% of RWC Asset Management LLP’s holdings, making the stock its 6th biggest position. RWC Asset Management LLP’s holdings in Johnson & Johnson were worth $51,100,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Clark Asset Management LLC boosted its stake in shares of Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after acquiring an additional 3,025 shares during the period. Treasurer of the State of North Carolina boosted its stake in Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after purchasing an additional 94,957 shares during the period. Avanza Fonder AB raised its position in shares of Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock valued at $35,842,000 after buying an additional 6,566 shares during the last quarter. Talbot Financial LLC lifted its holdings in shares of Johnson & Johnson by 4.6% in the third quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock worth $25,667,000 after buying an additional 6,143 shares in the last quarter. Finally, Winnow Wealth LLC bought a new position in shares of Johnson & Johnson during the second quarter worth $295,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive Phase 3 MajesTEC‑9 results: J&J reported topline data showing TECVAYLI (teclistamab) monotherapy cut risk of progression or death by 71% and reduced risk of death by 40% versus standard of care in a hard‑to‑treat multiple myeloma cohort — a result that supports TECVAYLI as a potential earlier standard of care and strengthens future revenue and label expansion prospects. TECVAYLI monotherapy demonstrates superior progression-free and overall survival
• Positive Sentiment: Additional Phase 3 confirmation: Separate coverage highlights Tecvayli’s Phase 3 results showing reduced progression and extended survival in pretreated multiple myeloma patients with manageable safety — reinforcing commercial upside if approvals/label expansions follow. Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients
• Positive Sentiment: Legal relief in Auris litigation: J&J won a partial reversal of a roughly $1B loss in the Auris case, reducing a sizable litigation overhang and lowering potential cash/earnings risk tied to the matter. That legal win supports sentiment and removes a tail‑risk. Johnson & Johnson wins partial reversal of $1B Auris case loss
• Neutral Sentiment: Analyst commentary and investor attention: Recent analyst notes review J&J’s fundamentals ahead of the Q4 print and compare J&J to peers; these discussions are keeping the name in focus but do not change near‑term fundamentals by themselves. Analysts Offer Insights on Healthcare Companies
• Neutral Sentiment: Earnings preview and metrics deep‑dive: Coverage previewing J&J’s upcoming Q4 release highlights key non‑GAAP metrics and items to watch (pipeline updates, margin drivers, guidance) — useful for positioning but outcome‑dependent. Exploring Analyst Estimates for Johnson & Johnson (JNJ) Q4 Earnings
• Negative Sentiment: Uncertain beat potential into earnings: Some previews suggest J&J may not have the mix needed for an earnings beat, implying the quarterly report could disappoint relative to expectations and introduce short‑term downside if guidance or key metrics miss. Johnson & Johnson (JNJ) Reports Next Week

Analyst Ratings Changes

Several equities research analysts have recently issued reports on JNJ shares. HSBC reaffirmed a “buy” rating and issued a $240.00 target price on shares of Johnson & Johnson in a report on Wednesday, December 10th. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Wells Fargo & Company raised their target price on shares of Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Stifel Nicolaus upped their price target on shares of Johnson & Johnson from $165.00 to $190.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. Finally, Bank of America lifted their price objective on shares of Johnson & Johnson from $204.00 to $220.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $213.33.

Johnson & Johnson Stock Performance

JNJ stock opened at $219.62 on Friday. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $219.75. The business has a 50-day moving average price of $205.18 and a 200 day moving average price of $186.28. The company has a market capitalization of $529.13 billion, a P/E ratio of 21.20, a PEG ratio of 2.24 and a beta of 0.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.76 by $0.04. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The business had revenue of $23.99 billion for the quarter, compared to analysts’ expectations of $23.73 billion. During the same quarter last year, the firm earned $2.42 EPS. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.